Market Cap | 14.02M | P/E | - | EPS this Y | - | Ern Qtrly Grth | 50.80% |
Income | 314k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 9.00% |
Sales | 26k | PEG | - | EPS past 5Y | 125.09% | 200D Avg Chg | -19.00% |
Dividend | N/A | Price/Book | 4.61 | EPS next 5Y | - | 52W High Chg | -58.00% |
Recommedations | - | Quick Ratio | 112.75 | Shares Outstanding | 74.21M | 52W Low Chg | 57.00% |
Insider Own | 10.84% | ROA | -1.46% | Shares Float | 30.11M | Beta | 0.49 |
Inst Own | 48.58% | ROE | 3.42% | Shares Shorted/Prior | 259.38K/298.38K | Price | 0.19 |
Gross Margin | 100.00% | Profit Margin | 6,111.54% | Avg. Volume | 18,054 | Target Price | - |
Oper. Margin | -1,250.00% | Earnings Date | Nov 7 | Volume | 500 | Change | -5.56% |
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
READ RANDOLPH C | Director Director | Nov 18 | Buy | 0.15 | 100,450 | 15,068 | 100,450 | 11/18/20 |